Claims 2025 Navigating an Increasingly Difficult and Complex World for Life Science Companies

In our annual end of year claims webinar, Andy Hall (Executive Claims Specialist—Medmarc) and Ricky C. Benjamin (Partner - Head of Life Sciences Industry Practice - Burr & Forman, LLP) gave an update on the claims and legal environment for life science companies. Topics discussed included: • GLP-1s and compounding pharmacies; • Laboratory developed tests and legal challenges over their regulation; • An update on Loper Bright and outside entities’ ability to challenge administrative decisions; • The admissibility of 510(k) evidence in life science matters; and • An update on important verdicts and legal decisions. Which topic most intrigued you? Let us know! 00:00 - Introduction of the Presenters 03:11 - Admissibility of 510(k) evidence 12:04 - GLP-1s? Wonder drug? Litigation target? Both? 26:27 - Loper Bright—A year later 32:48 - Recent developments with LDTs 47:05 - Autism and Tylenol—still a litigation issue? 54:50 - Closing